Previously untreated systemic anaplastic large cell lymphoma (sALCL)

Active Ingredient: Brentuximab vedotin

Indication for Brentuximab vedotin

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).

For this indication, competent medicine agencies globally authorize below treatments:

1.8 mg/kg once every 3 weeks for 6-8 cycles

For:

Dosage regimens

Intravenous, 1.8 milligrams brentuximab vedotin per kilogram of body weight, once every 3 weeks, 6 to 8 doses in total.

Detailed description

The recommended dose in combination with chemotherapy (cyclophosphamide [C], doxorubicin [H] and prednisone [P] [CHP]) is 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks for 6 to 8 cycles.

Primary prophylaxis with G-CSF, beginning with the first dose, is recommended for all adult patients with previously untreated sALCL receiving combination therapy.

Refer to the SmPCs of chemotherapy agents given in combination with brentuximab vedotin for patients with previously untreated sALCL.

General

If the patient’s weight is more than 100 kg, the dose calculation should use 100 kg.

Complete blood counts should be monitored prior to administration of each dose of this treatment.

Patients should be monitored during and after infusion.

Dosage considerations

The recommended dose of brentuximab vedotin is infused over 30 minutes.

Brentuximab vedotin must not be administered as an intravenous push or bolus. Brentuximab vedotin should be administered through a dedicated intravenous line and it must not be mixed with other medicinal products.

Active ingredient

Brentuximab vedotin

Brentuximab vedotin is an ADC that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells. Because of the CD30-targeted mechanism of action brentuximab vedotin is able to overcome chemo-resistance as CD30 is consistently expressed in patients who are refractory to multi-agent chemotherapy, irrespective of prior transplant status.

Read more about Brentuximab vedotin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.